MeiraGTx Holdings plc Ordinary Shares
MGTXMeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing treatments for rare and serious diseases. Based in the UK, the company specializes in creating advanced gene therapy products using proprietary platforms to deliver potentially curative therapies for conditions such as neurological, ophthalmic, and infectious diseases.
Company News
Eli Lilly signed a strategic collaboration with MeiraGTx for ophthalmology gene therapy, granting worldwide exclusive rights to AAV-AIPL1 program for Leber congenital amaurosis 4, with an upfront payment of $75 million and potential milestone payments over $400 million.
MeiraGTx reported Q2 2025 results with significant revenue growth but missed analyst estimates. The company advanced several gene therapy programs, secured key partnerships, and maintained strong manufacturing capabilities despite ongoing financial challenges.
A comprehensive analysis reveals over 70 companies developing AAV gene therapies for hereditary retinal diseases, offering potential transformative treatments for vision restoration through advanced gene therapy techniques.
Coave Therapeutics, a company pioneering genetic medicines, has established a new Scientific Advisory Board (SAB) with renowned experts in AAV vector biology, gene therapy for ophthalmology and CNS diseases, and extra-hepatic gene delivery. The SAB will provide strategic guidance to support Coave's R&D initiatives and the development of its ALIGA...
The Parkinson's disease market is expected to grow significantly due to the introduction of emerging therapies, advancements in treatment options, and a rising prevalence of the condition.
